ACR-368 Updated Aug 21
The stock is a pure binary bet on the 2H 2026 Phase 2b interim readout in serous endometrial cancer, a positive result could drive a large move toward the $11.50 mean analyst target (implied upside ~377% from the $2.20 close), while a miss would likely be severe for a company whose cash only runs into Q2 2027. Watch company guidance for a firm interim date, and treat the 52% cORR maturing data and Fast Track designation as encouraging but not de-risked; note the Breakthrough designation was for the OncoSignature diagnostic assay, not the drug itself.
- Maturing Phase 2b data showed a 52% confirmed overall response rate (cORR) in serous endometrial cancer, reported with Q4/FY2025 results (8-K filed 2026-03-19; press release sentiment rated bullish, impact 8).
- FDA granted Fast Track designation for ACR-368 as a monotherapy in endometrial cancer, and Breakthrough Device designation for the ACR-368 OncoSignature assay (FDA-catalyst extraction dated 2026-03-19).
- The registrational-intent Phase 2b prespecified interim analysis plus all-comer (biopsy-independent) serous EC arm data is on track for 2H 2026, reaffirmed at the Aug 12, 2026 Q2 earnings update, a defined near-term catalyst.
- The 2H 2026 Phase 2b interim is a make-or-break binary on a micro-cap: the stock closed ~$2.20 (52-week range $1.27–$3.56), so a negative interim would hit equity value hard, with cash only funding operations into Q2 2027.
- Elevated bearish flow signals: SecBot's 90-day checklist flags a weighted short-volume ratio of ~0.475 over 51 sessions (FINRA daily short-sale flow, not short interest), plus multiple institutional trims/near-exits in recent 13F quarters.
- FINRA semi-monthly short interest of 1,355,015 shares (~3.17% of ESTIMATED shares outstanding, days-to-cover 4.30) as of the 2026-07-31 settlement.